Author: Natalia Fintelman-Rodrigues; Carolina Q. Sacramento; Carlyle Ribeiro Lima; Franklin Souza da Silva; André C. Ferreira; Mayara Mattos; Caroline S. de Freitas; Vinicius Cardoso Soares; Suelen da Silva Gomes Dias; Jairo R. Temerozo; Milene Miranda; Aline R. Matos; Fernando A. Bozza; Nicolas Carels; Carlos Roberto Alves; Marilda M. Siqueira; Patrícia T. Bozza; Thiago Moreno L. Souza
Title: Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production Document date: 2020_4_5
ID: 6zk0ioep_7
Snippet: The seriousness of COVID19 and the need for an immediate intervention, along with this series of observations with LPV, RTV and ATV, motivated us to evaluate the susceptibility of SARS-CoV-2 to ATV. Since ATV is available as a clinical treatment alone or in combination with RTV, both therapies were studied here, which for the first time describes that SARS-CoV-2 Mpro is a target for ATV. Further, ATV alone or withRTV could inhibit viral replicati.....
Document: The seriousness of COVID19 and the need for an immediate intervention, along with this series of observations with LPV, RTV and ATV, motivated us to evaluate the susceptibility of SARS-CoV-2 to ATV. Since ATV is available as a clinical treatment alone or in combination with RTV, both therapies were studied here, which for the first time describes that SARS-CoV-2 Mpro is a target for ATV. Further, ATV alone or withRTV could inhibit viral replication in cell culture models of infection that also prevented the release of a cytokine storm-associated mediators. Our timely data . CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.04.020925 doi: bioRxiv preprint 5 highlights an additional therapeutic approach against COVID-19 that should be considered for clinical trials.
Search related documents:
Co phrase search for related documents- cell culture and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- cell culture and infection cell culture model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- cell culture and SARS susceptibility: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- cell culture model and clinical treatment: 1, 2, 3
- cell culture model and infection cell culture model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- clinical treatment and immediate intervention: 1, 2, 3
- clinical treatment and RTV combination: 1
- clinical treatment and SARS susceptibility: 1, 2, 3, 4, 5, 6, 7, 8
- clinical trial and immediate intervention: 1, 2, 3, 4, 5, 6
- clinical trial and SARS susceptibility: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date